Company: BIVIW
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001520138-25-000343
Chunk: 72

Company: BIOVIE INC.
Filing Date: 2025-11-10
Form: 10-Q
Item: Part I, Item 2
Chunk 72
---
This report contains forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as
amended. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we
use the words “intends,” “estimates,” “predicts,” “potential,” “continues,”
“anticipates,” “plans,” “expects,” “believes,” “should,” “could,”
“may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking
statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements
to be materially different from those expressed or implied by forward-looking statements. These factors include, among others: our research
and development activities and distributor channel; compliance with regulatory requirements; and our ability to satisfy our capital needs
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements. 

You are cautioned not to place undue reliance
on the forward-looking statements in this report, which speak only as of the date of this report. Except as may be required by applicable
law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking
statements contained in this report as a result of new information or future events or developments, except as required by law. Thus,
you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking
statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the
Securities and Exchange Commission (the “SEC”) that attempt to advise interested parties of the risks, uncertainties and other
factors that may affect our business. 

The following discussion of the Company’s
financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing
elsewhere in this report. 

Management’s Discussion

BioVie Inc. (the “Company” or “we”
or “our”) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative
disorders and advanced liver disease.

Neurodegenerative Disease Program

The Company acquired the biopharmaceutical assets